Go to deals
Healthcare

Bioventix has completed a US$1.4 million sell-down of founder’s equity

Bioventix Plc has raised funds through a sell-down of the founder’s equity.

Bioventix was founded in 2003 as a biotechnology company specializing in the creation and supply of high-affinity sheep monoclonal antibodies (SMAs) for use in immunodiagnostics such as clinical blood testing.

Oaklins Cavendish’s sister firm finnCap, based in the UK, acted as financial advisor and broker in respect of the sell-down of the founder’s equity.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Geoff  Nash

Geoff Nash

Partner

London, United Kingdom
Oaklins Cavendish

Related deals

Laptaria cu Caimac has completed an IPO
Food & Beverage

Laptaria cu Caimac has completed an IPO

Laptaria cu Caimac has raised US$5 million through a private placement of shares on the ATS Market of BSE. The funds will be used for the development of the factory, namely, the construction of a bottle and jar washing station, utility systems and packaging storage.

Learn more
Alexandria Pankkiiriliike Oyj has raised US$9.7m in the course of its IPO on NASDAQ First North Finland
Financial Services

Alexandria Pankkiiriliike Oyj has raised US$9.7m in the course of its IPO on NASDAQ First North Finland

Alexandria Pankkiiriliike Oyj (Alexandria) has raised US$9.7 million in the course of its IPO.

Learn more
Crimson Tide has completed a primary placing and secondary sell-down
TMT

Crimson Tide has completed a primary placing and secondary sell-down

Crimson Tide Plc has raised funds to invest in further developing its core product, in a new product aimed at micro/nano businesses and in marketing capabilities.

Learn more